INTRODUCTION {#S1}
============

The role of pharmacist in health care delivery continues to evolve beyond dispensing and directly related activities.[@B1],[@B2] Numerous studies has been shown pharmacist make valuable contributions to improve clinical, economic, and humanistic patients' outcomes.[@B3]-[@B29] Furthermore, many studies have evaluated the role of the pharmacist especially in intensive care unit (ICU).[@B4],[@B6]-[@B9],[@B20],[@B22],[@B23],[@B26] The rationale for putting a pharmacist in an ICU is that those patients are sicker and thus require a greater complexity of care. Having a pharmacist on a team in an ICU has been shown to reduce the incidence of adverse drug events (ADEs)[@B4],[@B25],[@B29] and decrease costs associated with care.[@B3],[@B22],[@B23],[@B25],[@B27]-[@B29] However, the study of the impact of pharmacist's interventions in intensive care unit in Thailand are limited.

As a result, we conducted a study of the effectiveness of pharmacist participation in a multidisciplinary team in medical ICU to provide optimal patient care through avoidance or treatment of drug related problems. The objectives of the study were to determine the type and quantity of patient care interventions recommended by a pharmacist and to specifically examine cost saving and cost avoidance that resulted from pharmacist recommendations in medical ICU.

METHODS {#S2}
=======

Setting, design, and sample {#S3}
---------------------------

The study carried out in 2 medical ICUs at Buddhachinaraj Hospital, a large tertiary care hospital (940-bed size hospital), in Phitsanulok province, Thailand, during February 28, 2005, through April 1, 2005. There are 20 beds in each unit. Patients were admitted to ICU based on disease severity and physician's judgment for appropriated care.

Both of two units were included in the study, one as the intervention group and the other as the control group. Patients had equal chance of being admitted to the control group or the intervention group. The admitting process was based on the availability of beds and physician service. The demographics and Acute Physiology and Chronic Health Evaluation (APACHE) scores in both groups were compared to determine if they were similar. We compared outcome, direct drug cost and length of ICU stay (LOS), between the study group and control group during the same period. For the study group, we calculated cost saving and cost avoidance resulted from pharmacist intervention. This study was approved by the Institutional Review Board/Human Subject Research Committee at Buddhachinaraj Hospital.

Pharmacist's activities and interventions {#S4}
-----------------------------------------

The treatment team consisted of a medical intensive care team plus a clinically trained pharmacist with a Pharm.D degree. Before morning rounds each day, the pharmacist reviewed all patient profiles and relevant data, including the physician's orders, laboratories, progress and consultation notes as appropriate, and formulated plans for modifying individual patient regimens. The pharmacist then participated in morning rounds. This provided an opportunity for the pharmacist to evaluate the treatment and suggest changes in patient drug regimens. After rounds, both newly admitted patients and patients previously admitted to the ward were discussed. The pharmacist suggestions for modifying therapy were presented. The pharmacist was full responsibility for providing drug information, pharmacotherapeutic consultation, and relevant as needed for five days a week. During 8.00 a.m. to 5.00 p.m. of the day, pharmacist maintained contact with the team physicians as needed. In all case, the pharmacist aimed to provide optimal patient care through avoidance or treatment of drug related problem, base on literature. All interventions were documented in the data collecting form.

Data analysis {#S5}
-------------

To perform analysis of the result, each intervention was assigned to an intervention category. The categorization of interventions was then verified by the clinical pharmacists. Since there is no standardized method of categorizing interventions made by pharmacist, the interventions were assigned to the categories used by Leape and colleagues[@B4] in an intervention illustrating the benefit of a pharmacist in an ICU unit. The interventions that accepted and implemented by team were also categorized as either cost saving and/or cost avoidance.

Cost saving {#S6}
-----------

Intervention that resulted in drug treatment with a lower or higher direct drug cost was evaluated in term of cost saving. Cost saving were calculated as the difference in actual costs between the previous therapy and the new therapy that was recommended by the pharmacist. Labor cost, supplies cost, or other indirect costs were not included in any calculation.[@B3],[@B22],[@B23] The saving resulting from the change in drug therapy was

generally assumed to extend to the end of therapy with the new agent.[@B3],[@B11],[@B22],[@B30] In the case of conversion from intravenous (i.v.) to oral dosage forms, the cost difference between the dosage forms was calculated for 2 days after the switch (it assumed that without the pharmacist's interventions, physician would have switched to oral dosage forms within 2 days).[@B11],[@B22]

The formula we used to estimate cost saving is in common use equation[@B11],[@B23]: Cost difference in USD = (cost of drug therapy multiple by frequency per day and multiple by duration of therapy, assumed to extend to the end of therapy with the new agent, before intervention) minus (cost of drug therapy multiple by frequency per day and multiple by duration of therapy after intervention plus cost of drug that was used before intervention).

Example 1. A patient was receiving ceftazidime (1 g every 8 hrs) to treat Pseudomonas aeruginosa. Three days later, patient's renal function was worsening; calculated creatinine clearance was 16.6 ml/min. The pharmacist then gave team an intervention. After intervention, the order was changed, base on renal guideline, to ceftazidime (1 g every 24 hrs). The duration of therapy was 7 days. The cost of each 1 g-vial of ceftazidime was 1.7 USD. So, the cost for this case is, (1.7 USD/1 g-vial × 3 times/day × 7 days) -- \[(1.7 USD/1 g-vial × 1 time/day × 4 days) + (1.7 USD/1 g-vial × 3 times/day × 3 days)\], 13.6 USD. It means 13.6 USD decreased or saved.

Example 2. A patient with underlying diabetes whose blood was sent to measure electrolyte and trace element. When the result came back, pharmacist screened and saw the potassium concentration result was 8 mEq/L (K=8 mEq/L). The pharmacist then gave team an intervention. After intervention, physician ordered Kayexalate 30 g every 4 hrs for 4 doses. The cost of 30 g-powder packed Kayexalate is 4.7 USD. Thus, the cost for this case is, (4.7 USD/30 g-powder packed Kayexalate × 4 doses), 18.8 USD. It means 18.8 USD increased. In contrast, this intervention, trough monitoring potassium and prevention of serious cardiac complications and subsequent admission or may be death, was calculated as cost avoidance as well.

The net cost saving over the duration of study period was calculated by subtracting the total decrease in drug costs from the total increase in drug costs.

Cost avoidance {#S7}
--------------

The intervention with potential to avoid an adverse drug events (ADE) were assessed for cost avoidance by a member panel of clinical specialists.[@B28]-[@B30] The panel comprised seven members. Four members with doctor of pharmacy degree, three of the seven members had completed master's degree and had been experienced in ADR center for many years, and one of them was a clinical pharmacy specialist instructor who holds the Ph.D. degree and Board Certified Pharmacotherapy Specialist.

The panel evaluated each intervention to estimate the probability, in the absence of the intervention, of an ADE occurring on the basis of the clinical details surrounding the intervention. The probability of an ADE in the absence of the intervention was set at 0 (zero; e.g. information requested), 0.01 (very low; for problem orders e.g. clarifications, missing information, nonexistent strengths), 0.1 (low; for prevented a potentially significant reaction e.g. 2-4 × normal dose, dose inadequate to produce therapeutic effect; incorrect schedule/route with potential for therapeutic failure/toxicity; duplicate therapy with potential for additive toxicity), 0.4 (medium; for prevented a potentially serious reaction e.g. allergy to drug ordered, no allergy information, 4-10 × normal dose; no adjustment of renal failure), 0.6 (high; for prevented a potentially fatal or severe reaction e.g. 10 × normal dose; narrow therapeutic range; life-threatening reaction/anaphylaxis).[@B11],[@B30] Literature was used to assign probability estimates, when available. When no literature estimate was available, judgment based on patient's clinical data was used to assign the intervention to a probability category.[@B30] We assumed that no intervention would increase the likelihood of a preventable ADE. The cost of each adverse event was set at 53 USD on the basis of average cost of adverse drug reaction form the previous trial.[@B31] Cost avoidance was calculated for each intervention by multiplying the estimated probability of an ADE in the absence of the intervention with the average cost of an ADE (53 USD).[@B29],[@B30]

Example: A patient with pneumonia was receiving amoxicillin/clavulanate potassium (1000 mg/ 200 mg every 8 hrs) to treat Stapphylococcus aureus. The pharmacist calculated creatinine clearance; it was 12.5 ml/min. The pharmacist then gave team an intervention. After intervention, the order was changed, base on renal guideline, to amoxicillin/clavulanate potassium (1000 mg/ 200 mg every 12 hrs). The panel estimated the probability of an ADE, in the absence of the intervention, was 0.4 (medium). So, the cost avoidance of this case is, (0.4 × 53), 21.2 USD.

The net change in drug costs over the duration of study period calculated by cost saving plus cost avoidance. All cost in Thai baht (THB) was converted to US dollars (1 USD about 38.36 THB).

Statistical analysis {#S8}
--------------------

Patient variables between the study and control group were compared using chi-square analysis for sex and Mann-Whitney U test for age, APACHE score, direct drug cost, and length of stay (LOS).[@B32] The level significance was set at 0.05.

RESULTS {#S9}
=======

There were 65 patients admitted to the medical ICU during the study days. There was not significantly different with respect to age, sex, and APACHE score between study and control groups ([Table 1](#T1){ref-type="table"}).

###### 

Patient Characteristics

  ------------------------- -------------------- ---------------------- -----------
  Characteristic            Study group (n=32)   Control group (n=33)   *P* Value
  Age, mean (SD), year      62.66 (14.49)        65.00 (15.16)          0.527
  Sex, No. (%)                                                          
  Male                      18 (56.25)           18 (54.55)             0.890
  Female                    14 (43.75)           15 (45.45)             0.890
  APACHE score, mean (SD)   17.31 (8.09)         19.75 (8.51)           0.240
  ------------------------- -------------------- ---------------------- -----------

APACHE = Acute Physiology and Chronic Health Evaluation

In term of direct drug cost per capita, it was 1,076.37 USD in study group compared with 1,258.38 USD in control group. The difference of direct drug cost between two group was 182.01 USD, but did not statistical significant (p=0.138). The average LOS was 7.16 days (SD 6.62) in the study group and 6.18 days (SD 3.79) in the control group (p=0.995) ([Table 2](#T2){ref-type="table"}).

###### 

Direct Drug Cost and Length of ICU Stay Comparisons

  ------------------------------------ -------------------- ---------------------- -----------
  Comparator                           Study group (n=32)   Control group (n=33)   *P* Value
  ICU drug cost, USD                   34,443.80            35,530.79              0.138
  ICU drug cost per capital, USD       1,076.37             1,258.38               0.138
  Length of ICU Stay, mean (SD), day   7.16 (6.62)          6.18 (3.79)            0.995
  ------------------------------------ -------------------- ---------------------- -----------

Of the 127 interventions provided by pharmacist, 125 interventions accepted and implemented by team (98.4%). These interventions were categorized and analyzed as either cost saving and/or cost avoidance. Interventions made by pharmacist resulted in direct cost saving of 1,971.43 USD and cost avoidance of 294.62 USD during study period. The total cost saving and cost avoidance was 2,266.05 USD ([Table 3](#T3){ref-type="table"}). The most common intervention was "providing required information on written orders" followed by "the team initiated for help and adjust dose per renal dosing guideline" ([Table 3](#T3){ref-type="table"}).

###### 

Cost saving and cost avoidance classified by interventions (Study group)

  ------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------- ------------------- ---------------------- ------------------------------------
  Intervention                                                                                                                         No. of Interventions n = 127 (%)   Cost Saving (USD)   Cost Avoidance (USD)   Total cost Saved and avoided (USD)
  Missing required information on written prescriptions/orders                                                                         33 (25.98)                         -306.28             -18.02                 -324.30
  Team initiated request for help (e.g. drug storage, compatibility, etc.)                                                             27 (21.26)                         0.00                -8.48                  -8.48
  Adjust dose per renal dosing guideline                                                                                               20 (15.75)                         -599.97             -167.98                -767.95
  Drug-drug interactions                                                                                                               10 (7.87)                          0.00                -12.72                 -12.72
  Recommend antibiotic coverage (empiric therapy, change or discontinue after culture and sensitivity result, and length of therapy)   10 (7.87)                          -875.42             -14.31                 -889.72
  Recommend supplement therapy (e.g. K, Mg, Ca)                                                                                        9 (7.09)                           30.24               -16.96                 13.28
  Inappropriate schedule, dose, rate, or frequency prescribed for indication                                                           7 (5.51)                           -69.53              -38.15                 -107.68
  TPN/Enteral nutrition monitoring/intervention                                                                                        3 (2.36)                           9.96                -0.53                  9.43
  Recommend switching route of administration as appropriate (e.g. IV to PO when NG out)                                               2 (1.57)                           -160.43             0.00                   -160.43
  Recommend to check laboratory for appropriate therapy                                                                                2 (1.57)                           0.00                -5.83                  -5.83
  Recommend stopping contraindicated drugs                                                                                             1 (0.79)                           0.00                -0.53                  -0.53
  Wrong unit of measure (e.g. mg instead of mcg)                                                                                       1 (0.79)                           0.00                -5.30                  -5.30
  Miscellaneous                                                                                                                        2 (1.57)                           0.00                -5.83                  -5.83
  Total                                                                                                                                127 (100)                          -1,971.43           -294.62                -2,266.05
  ------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------- ------------------- ---------------------- ------------------------------------

\- indicated decrease cost of drug therapy

In addition, cost saving and cost avoidance were classified by drug class. We found that anti-infective was the major cost reduction (1,958.61 USD) followed by anticoagulants (132.36 USD). The most common drugs used in ICU were anti-infective, cardiovascular drugs, electrolytes trace elements and fluid, and anticoagulants, respectively, which required more interventions than other drugs ([Table 4](#T4){ref-type="table"}).

###### 

Cost saving and cost avoidance classified by drug classes (Study group)

  ----------------------------------------- ---------------------------------- ------------------- ---------------------- ------------------------------------
  Drug classes                              No. of Interventions n = 127 (%)   Cost Saving (USD)   Cost Avoidance (USD)   Total cost Saved and avoided (USD)
  Antiinfectives                            51 (40.16)                         -1,750.89           -207.72                -1,958.61
  Cardiovascular drugs                      18 (14.17)                         0.55                -19.08                 -18.53
  Electrolytes, trace elements, and Fluid   15 (11.81)                         2.09                -17.49                 -15.40
  Anticoagulants                            14 (11.02)                         -102.69             -29.67                 -132.36
  Psychoactive and CNS agents               6 (4.72)                           0.00                -6.36                  -6.36
  Gastrointestinal drugs                    5 (3.94)                           1.82                -1.06                  0.77
  Antidiabetic agents, Insulin              2 (1.57)                           0.00                -5.83                  -5.83
  Antiasthmatic agents                      2 (1.57)                           0.00                0.00                   0.00
  Analgesics                                1 (0.79)                           0.00                0.00                   0.00
  Others[\*](#t4fn2){ref-type="fn"}         13 (10.24)                         -122.31             -7.42                  -129.73
  Total                                     127 (100)                          -1,971.43           -294.62                -2,266.05
  ----------------------------------------- ---------------------------------- ------------------- ---------------------- ------------------------------------

\- indicated decrease cost of drug therapy

Others drug or cannot classified into drug class e.g. TPN/Enteral intervention

DISCUSSION {#S10}
==========

The number of adverse drug events and the subsequent cost of these events can be reduced by pharmacist intervention.[@B3]-[@B5],[@B10]-[@B18] In the current study, we aims to describe the characteristics of the interventions and to determine pharmacist's interventions led to change in cost saving and cost avoidance in an intensive care unit (ICU). This study documented a role for a pharmacist in a multidisciplinary ICU, and demonstrated a substantial reduction in drug costs as a result of pharmacist - initiated therapeutic consultations / interventions.

Critically ill patients with multiple system disease require multiple drug therapy; in addition, changes in their pharmacokinetic and pharmacodynamic variables due to multiple organ dysfunctions can affect the absorption, metabolism, elimination, and interaction of drugs. Thus, critical ill patients present unique pharmacologic challenges to the clinician. Although these challenges may be similar to those in general or surgical patients, their frequency and importance are increased in the ICU population.[@B23]

Monitoring for adverse drug reactions was an importance responsibility of the pharmacist. Many medications taken by ICU patients have significant adverse effect profiles and multiple known drug-drug interactions.

In addition to direct patient care activities, the pharmacist provided in-service education to the team, participated in research, and identified indigent patients and enrolled them in medication assistance programs. Other professionals on the team indicated that the direct (e.g. pharmacotherapy recommendations) and indirect (e.g. drug information) services provided made the pharmacist a valuable member of the team.

In our study documented that the 98% percent of the pharmacist's interventions were accepted and implemented by team exceeds the overall 95% acceptance rate (8.7% accepted with changing therapy) previously reported for pharmacists' recommendations.[@B20] The quality and importance of the pharmacist's interventions are reflected in the independent evaluation of potential impact on patient care. Similarly favorable results have been reported in other centers despite some variability in the calculation of savings. For example, Bearce and colleagues[@B33] multiplied the cost difference per day by the number of days that the patient was in ICU, regardless of whether the patient remained on the drug in question for the entire stay or not. Warrian and Irvince-Meek[@B34] multiplied the cost difference per day by the average length of stay. However, calculating the cost difference based on the number of days the patient was receiving therapy fails to capture the benefit of a consultation that led to discontinuing a drug-one cannot know how many days this drug would have been continued if the consultation were not made. We believe that our approach to drug cost is as reasonable as others employed.

There are limitations to the conclusion of this study. First, the crude cost calculations do not include the pharmacist's time spent in chart review and making rounds with the team to identify potentially meaningful interventions. Furthermore, according to the pilot study, the sample size in this study was not calculated and got very small size that reflect the fact that there is not enough statistical power to detect the significant different between two groups. However, the results in cost saving and cost avoidance in the study group tend to be reduced. In addition, it is likely that not every pharmacist would demonstrate the same skill level as the others. Thus, these finding may not necessarily be extrapolated to other clinical pharmacist in other institutions.

Our study demonstrated that the participation of a clinical pharmacist in patient care rounds, chart review, and providing interventions resulted in benefits in term of cost saving and cost avoidance. These results suggest that a dedicated clinical pharmacist in ICU by providing interventions is likely to decrease total drug cost and play a crucial role on the ICU team.

CONCLUSIONS {#S11}
===========

Our results indicated that a pharmacist's interventions in intensive care unit had a positive potential impact on overall drug cost, cost saving, and cost avoidance and were well accepted by the team. The need to further develop the methodology to estimate the cost will be a major challenge. More studies are needed in this field.
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